- Home
- DC vs LYEL Comparison
DC vs LYEL Comparison
Compare DC & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$6.63
HOLD
Current Price
$25.23
Company Overview
Basic Information| Metric | DC | LYEL |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.7M | 504.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DC | LYEL |
|---|---|---|
| Price | $6.63 | $25.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $9.38 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.5M | 113.7K |
| Earning Date | 11-13-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $7.65 |
| 52 Week High | $7.25 | $45.00 |
Technical Indicators
Market Signals| Indicator | DC | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 45.82 |
| Support Level | $6.21 | $24.57 |
| Resistance Level | $7.25 | $27.89 |
| Average True Range (ATR) | 0.39 | 1.68 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 64.89 | 51.36 |
Price Performance
Historical Comparison DC
LYEL
About DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine. Company project includes Richmond Hill Project.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.